



Myelodysplastic Syndrome (MDS) FISH Panel

Targeted Analysis for Diagnosis, Prognosis, and Monitoring

Fluorescence In Situ Hybridization (FISH) is a highly sensitive method for detecting chromosomal abnormalities associated with Myelodysplastic Syndromes (MDS). The EmeritusDX MDS FISH Panel identifies recurrent cytogenetic abnormalities that aid in diagnosis, risk stratification, prognostic assessment, and disease monitoring.

Why Order MDS FISH?

- Detect clinically significant chromosomal abnormalities associated with MDS
- Complement conventional chromosome analysis (karyotyping)
- Identify abnormalities in cases with insufficient or poor-quality metaphases
- Support IPSS-R and IPSS-M risk stratification
- Aid in diagnosis, prognosis, and longitudinal disease monitoring

Clinical Applications:

- Evaluation of suspected MDS
- Persistent unexplained cytopenias
- Abnormal CBC findings
- Disease monitoring and follow-up
- Assessment of disease progression

Why EmeritusDX?

- Comprehensive hematologic diagnostic services
- Integrated FISH, Flow Cytometry, Molecular, Cytogenetic, and Hematopathology testing
- Expert interpretation by board-certified specialists
- TAT: 3-5 Days
- CAP-Accredited
- CLIA-Certified

MDS FISH Panel Targets:

- 5q31 (EGR1)
- 7q31 (D7S486)
- Cen 8
- 20q12
- 17p13 (TP53)

